

BIOGRAPHICAL SKETCH

NAME: Marco Cipolli

POSITION TITLE: Director of the Cystic Fibrosis Center of Verona

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)*

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	Completion Date MM/YYYY	FIELD OF STUDY
University of Verona, Italy	M.D.	11/1985	Medicine and Surgery
University of Verona, Italy	Residency	07/1990	Pediatrics
Scuola Superiore di Oncologia e Scienze Biomediche, Genoa, Italy	Advanced course	09/1991	Statistical analysis in clinical trials
International School of Oncology and Experimental Medicine, Rome, Italy	Advanced course	11/1993	Implementation and management of clinical trials
University of Verona, Italy	Residency	10/1994	Gastroenterology and Digestive endoscopy
University of Verona, Italy	Advanced Course	07/1999	Survival analysis

A. Personal Statement

Since 1985 I have been working in pediatrics, initially following infectious diseases. In 1988 I began to work in cystic fibrosis focusing my attention to respiratory aspects. Since 1991 I have been studying also gastroenterological aspects, in particular liver and pancreatic issues of both cystic fibrosis and non-cystic fibrosis patients. In the same year I began to follow patients with Shwachman-Diamond syndrome studying phenotypical and epidemiological aspects. In fact, since 1995 I have been coordinating the Italian Registry of SDS patients. In 2014 I became the Head of the first Regional Center of Shwachman-Diamond syndrome (Verona, Italy), following almost 40 patients with SDS. From 2008 to 2016 I directed the Clinical Research Center at the Cystic Fibrosis Center of Verona, Italy, coordinating almost 20 clinical studies in cystic fibrosis. In 2016 I have directed the Cystic Fibrosis Center of Ancona, Italy, following also more than 30 patients with SDS coming from the Italian central regions. Since September 2019 I have been heading the Cystic Fibrosis Center of Verona, which is one of the largest CF center of Europe.

B. Positions and Honors

- 1992-1997 Assistant doctor at Cystic Fibrosis Center, Verona, Italy
- 1997-2016 Head of the Gastroenterological Clinic Service at the Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
- 2008-2016 Director of the Clinical Research Center at Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
- 2010- Director of the scientific committee of Associazione Italiana Sindrome di Shwachman (AISS)

Marco Cipolli Biosketch

- 2016-2019 Director of the Cystic Fibrosis Center, Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona, Italy
- 2019- Director of the Cystic Fibrosis Center of Verona, Italy

Other Experience and Professional Memberships (selection) Participation in the following clinical trials:

- | | |
|-----------|--|
| 1993 | BAY o 9867/1370, Phase III, Sub-Investigator |
| 1996 | AZITRO/96, Phase III, Principal Investigator |
| 1996 | PAN 96-1-CF, Phase III, Sub-Investigator |
| 2001 | S2483003, Phase III, Principal Investigator |
| 2007 | ALTUS 0000726, Phase III, Principal Investigator |
| 2008 | ALTUS 0000767, Phase III, Principal Investigator |
| 2008 | AZLI GS-US-205-0110, Phase III, Sub-Investigator |
| 2010 | EUR-1008, Phase III, Principal Investigator |
| 2010 | VR496, Phase I/II, Sub-Investigator |
| 2011 | 205.438, Phase III, Principal Investigator |
| 2012-2013 | TR02-108, Phase III, Principal Investigator |
| 2012-2013 | TR02-110, Phase III, Principal Investigator |
| 2012-2013 | TIP, Phase IV, Principal Investigator |
| 2013-2014 | TIP extension, Phase IV Principal Investigator |
| 2013-2014 | VERTEX 103, Phase III, Principal Investigator |
| 2014-2015 | VERTEX 105, Phase III, Principal Investigator |
| 2015-2016 | VERTEX 106, Phase III, Principal Investigator |
| 2015-2016 | VERTEX 108, Phase III, Principal Investigator |
| 2015-2016 | PRO-QR, Phase IB, Principal Investigator |
| 2018 | VERTEX-VX17-445-102. Phase III, Principal Investigator |
- 2001- Member of the medical and scientific advisory board (MSAB) of the US SDS Foundation, from
- 2003-2005 Chief of the MSAB of the US SDS Foundation
- 2016-2019 Vice-President of the Italian Society of Cystic Fibrosis
- 2020- President of the Italian Society of Cystic Fibrosis

C. Contributions to Science

PUBLICATIONS (updated on September, 2019, Scopus Source)

61 publications (h-index 18, Total citations 1671) including 52 articles in peer-reviewed International Journals, 5 reviews, 4 letters

Complete list of published works in researcher unique identifiers:

0000-0001-6646-421X (ORCID)

A-6673-2017 (Researcher ID)

4. Vertex Pharmaceuticals IIS (Cipolli, PI) 08/07/18-08/06/2021

“Clinical Follow-up of CF patients carrying a residual function mutation: a five years cohort Italian study”. Management of the entire multicentric clinical study.

1. Italian Cystic Fibrosis Foundation (Cipolli, Partner) 09/01/18-08/31/20

“Cystic Fibrosis Screen Positive Inconclusive Diagnosis (CFSPID): an Italian multicenter survey evaluating prevalence, clinical data, management and outcome”. The main goal of this project are: 1. to evaluate retrospectively prevalence, genetic and clinical data, management and outcome of CFSPID patients followed from 01.01.2011 to 31.08.2018 in 6 Italian CF Centers; 2. to standardize prospectively the management of CFSPID infants born in the period 01.09.2018-31.12.2019.

2. Italian Cystic Fibrosis Foundation (Cipolli, Partner) 09/01/18-08/31/20

“Identification and validation of circulating microvesicle analysis as a new ex vivo assay to monitor cystic fibrosis disease”. The project aims at using microvesicles released by activated cells (from platelets, leukocytes, endothelial cells and also epithelial cells) during cystic fibrosis to monitor the activation status of inflammatory cells that would provide an integrated parameter of potential clinical value during cystic fibrosis.

3. Italian Cystic Fibrosis Foundation (Cipolli, Partner) 09/01/18-08/31/20 "Revealing the

microRNAs-transcription factors network in cystic fibrosis: from microRNA therapeutics to precision medicine (CF-miRNA-THER)". This project is aimed to evaluate the effect of pre-miRNA and antago-miRNA on CFTR expression and function in cells obtained from patients affected by cystic fibrosis.